Barely Significant
← all excerpts

Efficacy and safety of eptinezumab for migraine: A systematic review and meta-analysis.

J Res Med Sci · 2023 · PMC10826853 · PMID 38292336

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantP < 0.001actually significant
Secondary efficacy outcomes Three secondary efficacy outcomes were assessed, and in comparison, any dose of eptinezumab had a highly significant efficacy, ≥75% migraine responder rate [RR = 1. 80, 95% confidence interval (CI): 1.40, 2.33, P < 0.001 Figure 2 b], ≥50% migraine responder rate [RR = 1.46, 95% CI: 1.33, 1.61, P < 0.001 Figure 2 c], and 100% migraine responder rate [RR = 2.41, 95% CI: 1.08, 5.38, P = 0.03 Figure 2 d].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.